Home Company News  

Genepharm Opened its Second R&D Center in Taiwan

            Genepharm, specializing in the development and commercialization of preventive and curative therapeutics for skin-related problems, established its Taiwan subsidiary, Genepharm Biotechnology Cooperation (GBC), close to a year ago.  The company uses technology-led business model with unique marketing strategies which allows it to grow significantly in the short period of time. Other than setting up the market and sales channels at Taiwan for launching the skin treatment products, Dermesis, Genepharm expects to launch the products to the greater Asia in the near future.

            On January 31, 2008, Genepharm also opened a research and development facility at Taiwan Nankang Biotech Incubation Center. The first R&D center exists in its headquarter located at Sunnyvale, California. The center will focus on improving the formulations of existing topical drugs using two Genepharm’s patented technology, Calcium-T and Aero-Foli. The Calcium-T technology is a proprietary mineral complex that can effectively deliver the required amount of calcium and related ions into the epidermis for optimal skin barrier regeneration and homeostasis. The intended use is to be applied for post-photothermolysis treatment and adjunctive therapy of skin diseases. The Aero-Foli technology is a unique technology to effectively deliver the designated active compounds into follicular pathway and ensure the efficient transport of drugs after application on skin surface. This technology is applied in hair-related therapy and follicular drug delivery. The implementation of these two technologies on drug development will allow Genepharm to create opportunities for the new applications of topical drugs and over-the-counter (OTC) products of adjuvant skin therapy.

            Director of Industrial Development Bureau Ministry of Economic Affairs, Mr. Gou Zhen Lee, attended the opening ceremony of the R&D Center. He said that the Taiwan government completely supports the development of biotechnology.  The government even offers several tax benefits and incentives, emphasizes on patent protection law, and along with sufficient skillful workers to encourage the research and development through innovative processes. By taking advantage on these important elements favorable to the Taiwan biotechnology industry, Genepharm confidently focuses on the development of new topical drug to achieve tremendous growth potentials in the foreseeable future. (Jeff Liao)

From left to right: Dr. Xinfan Huang, Mr. Gou-Zhen Lee, Dr. George Lee, Mr. Min-Gee Wu,

Mr. Zun-Yan Wang, Mr. Fu-Lung Shih